Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 5/20 | 0.35 |
| ▸ | HTR3A | P46098 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | FPR1 | P21462 | 1/20 | 0.31 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.31 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24998625 | 0.85 | RORC (0.33) | HTR3ABRD4 | |
| SCHEMBL24997654 | 0.82 | SCN9A (0.35) | SCN9A | |
| SCHEMBL24998325 | 0.81 | CCR4 (0.37) | BRD4SCN9AFPR1TDP1RBP4 | |
| SCHEMBL25639319 | 0.74 | CDC7 (0.31) | SCN9A | |
| SCHEMBL24142758 | 0.72 | SCN9A (0.35) | BRD4SCN9A | |
| SCHEMBL30774090 | 0.72 | CCR4 (0.37) | HTR3ASCN9A | |
| SCHEMBL20552538 | 0.71 | SCN9A (0.35) | SCN9ATDP1 | |
| SCHEMBL25639270 | 0.71 | SCN9A (0.34) | SCN9A | |
| SCHEMBL24997647 | 0.70 | SCN9A (0.33) | SCN9A | |
| SCHEMBL24144681 | 0.69 | CCR4 (0.36) | HTR3ABRD4TDP1AAK1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | NR1D1 2426/4885HTR3A 4181/4885BRD4 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.